SAN DIEGO, Jan. 5 /PRNewswire/ -- ActiveSight announced that it has signed an expanded crystallography services agreement with Lexicon Pharmaceuticals. The agreement, the third between the companies, covers co-crystallography services for multiple proprietary targets of Lexicon Pharmaceuticals. ActiveSight's second co-crystallography agreement with Lexicon was announced in April of 2005. Lexicon Pharmaceuticals is the medicinal chemistry division of Lexicon Genetics Incorporated.
"We are delighted that Lexicon Pharmaceuticals has decided to expand their relationship with ActiveSight. We look forward to providing continued structural biology support for Lexicon's drug discovery programs," stated Duncan McRee, President of ActiveSight.
ActiveSight(TM) offers full gene-to-structure protein crystallography services, including fragment-based screening utilizing the Rigaku FR-E SuperBright(TM) generator and the ACTOR(TM) automation system. For more information visit www.active-sight.com.
ActiveSight and ACTOR are trademarks of Rigaku.